Malignant glioma: who benefits from adjuvant chemotherapy?

Ann Neurol. 1998 Oct;44(4):691-5. doi: 10.1002/ana.410440418.

Abstract

We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligo dendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / pathology
  • Brain Neoplasms / radiotherapy
  • Carmustine / therapeutic use
  • Chemotherapy, Adjuvant*
  • Combined Modality Therapy
  • Glioma / drug therapy*
  • Glioma / pathology
  • Glioma / radiotherapy
  • Humans
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Survival Analysis

Substances

  • Antineoplastic Agents, Alkylating
  • Carmustine